0001209191-17-021878.txt : 20170320
0001209191-17-021878.hdr.sgml : 20170320
20170320203515
ACCESSION NUMBER: 0001209191-17-021878
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20170309
FILED AS OF DATE: 20170320
DATE AS OF CHANGE: 20170320
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cascadian Therapeutics, Inc.
CENTRAL INDEX KEY: 0001412067
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 260868560
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2601 FOURTH AVENUE
STREET 2: SUITE 500
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: (206) 801-2100
MAIL ADDRESS:
STREET 1: 2601 FOURTH AVENUE
STREET 2: SUITE 500
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: Oncothyreon Inc.
DATE OF NAME CHANGE: 20070927
FORMER COMPANY:
FORMER CONFORMED NAME: Biomira CORP
DATE OF NAME CHANGE: 20070911
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Walker Luke Nathaniel
CENTRAL INDEX KEY: 0001701440
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33882
FILM NUMBER: 17702753
MAIL ADDRESS:
STREET 1: C/O CASCADIAN THERAPEUTICS, INC.
STREET 2: 2601 4TH AVE., SUITE 500
CITY: SEATTLE
STATE: WA
ZIP: 98121
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2017-03-09
0
0001412067
Cascadian Therapeutics, Inc.
CASC
0001701440
Walker Luke Nathaniel
C/O CASCADIAN THERAPEUTICS, INC.
2601 4TH AVE., SUITE 500
SEATTLE
WA
98121
0
1
0
0
SVP, Clinical Development
Common Stock
3990
D
Stock Option (right to buy)
35.88
2019-09-30
Common Stock
2500
D
Stock Option (right to buy)
41.52
2019-12-01
Common Stock
334
D
Stock Option (right to buy)
28.44
2020-12-12
Common Stock
1250
D
Stock Option (right to buy)
10.44
2021-12-12
Common Stock
2500
D
Stock Option (right to buy)
10.56
2022-12-16
Common Stock
1250
D
Stock Option (right to buy)
21.06
2023-09-24
Common Stock
5834
D
Stock Option (right to buy)
6.90
2024-05-17
Common Stock
8334
D
Stock Option (right to buy)
6.90
2024-05-17
Common Stock
20834
D
Stock Option (right to buy)
4.64
2027-01-11
Common Stock
35100
D
Restricted Share Unit (RSU)
2021-01-11
Common Stock
7800
D
The option was 100% vested on September 16, 2015.
The option was 100% vested on December 1, 2015.
The option was 100% vested on December 12, 2016.
The option vests and is exercisable at the rate of 1/4th of the total shares on December 12, 2014 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on December 12, 2017, subject to the holder's continued employment with the issuer on each vesting date.
The option vests and is exercisable at the rate of 1/4th of the total shares on December 16, 2015 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on December 16, 2018, subject to the holder's continued employment with the issuer on each vesting date.
The option vests and is exercisable at the rate of 1/4th of the total shares on September 24, 2016 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on September 24, 2019, subject to the holder's continued employment with the issuer on each vesting date.
The option vests and is exercisable at the rate of 1/4th of the total shares on May 17, 2017 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on May 17, 2020, subject to the holder's continued employment with the issuer on each vesting date.
The option vests and is exercisable at the rate of 1/4th of the total shares on April 1, 2017 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on April 1, 2020, subject to the holder's continued employment with the issuer on each vesting date.
The option vests and is exercisable at the rate of 1/4th of the total shares on January 11, 2018 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date.
Twenty-five percent of the shares underlying the RSU vest on each of January 11, 2018, January 11, 2019, January 11, 2020 and January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date.
Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs.
/s/ Julia M. Eastland as attorney-in-fact for Luke N. Walker
2017-03-20
EX-24.3_713261
2
poa.txt
POA DOCUMENT
LIMITED POWER OF ATTORNEY
The undersigned hereby constitutes and appoints Julia M. Eastland, as long as
she is providing services to Cascadian Therapeutics, Inc. (the "Company"), the
undersigned's true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer and/or director of the Company, Forms 3, 4s and 5s in accordance
with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the
rules and regulations thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute any such Forms 3, 4s and
5s and timely file such forms with the Securities and Exchange Commission and
any stock exchange or similar authority; and
(3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to such attorney-in-fact full power and authority
to do and perform each and every act and thing whatsoever requisite, necessary
or proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or could
do if personally present, with full power of substitution and revocation, hereby
ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that such attorney-in-fact, in serving in
such capacity at the request of the undersigned, is not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Exchange Act.
The undersigned agrees that such attorney-in-fact may rely entirely on
information furnished orally or in writing by the undersigned to such
attorney-in-fact. The undersigned also agrees to indemnify and hold harmless
the Company and such attorney-in-fact against any losses, claims, damages or
liabilities (or actions in these respects) that arise out of or are based on any
untrue statement or omission of necessary facts in the information provided by
the undersigned to such attorney-in-fact for purposes of executing,
acknowledging, delivering and filing Forms 3, 4s or 5s (including amendments
thereto) and agrees to reimburse the Company and such attorney-in-fact for any
legal or other expenses reasonably incurred in connection with investigating or
defending against any such loss, claim, damage, liability or action.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4s and 5s with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorney-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of March 17, 2017.
/s/ LUKE N. WALKER
Luke Nathaniel Walker, M.D.